Dynavax Technologies (NASDAQ:DVAX) COO David Novack Sells 114,000 Shares

Dynavax Technologies Corporation (NASDAQ:DVAX) COO David Novack sold 114,000 shares of the business’s stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $15.64, for a total transaction of $1,782,960.00. Following the sale, the chief operating officer directly owned 63,344 shares in the company, valued at $990,700.16. The trade was a 64.28% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Dynavax Technologies Price Performance

Shares of NASDAQ DVAX opened at $15.68 on Wednesday. The company has a 50 day simple moving average of $12.82 and a two-hundred day simple moving average of $11.23. Dynavax Technologies Corporation has a fifty-two week low of $9.20 and a fifty-two week high of $15.73. The company has a market capitalization of $1.84 billion, a price-to-earnings ratio of -42.38 and a beta of 0.89. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.94 and a current ratio of 7.62.

Dynavax Technologies (NASDAQ:DVAX) last posted its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported $0.21 earnings per share for the quarter, topping the consensus estimate of $0.14 by $0.07. The company had revenue of $94.88 million for the quarter, compared to the consensus estimate of $94.00 million. Dynavax Technologies had a positive return on equity of 7.18% and a negative net margin of 13.13%. Analysts expect that Dynavax Technologies Corporation will post 0.32 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on DVAX. Weiss Ratings reiterated a “sell (d)” rating on shares of Dynavax Technologies in a research note on Wednesday, October 8th. Wall Street Zen upgraded shares of Dynavax Technologies from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 27th. Finally, William Blair cut shares of Dynavax Technologies from an “outperform” rating to a “hold” rating in a report on Wednesday, December 24th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $24.33.

Hedge Funds Weigh In On Dynavax Technologies

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Blair William & Co. IL grew its stake in shares of Dynavax Technologies by 0.3% in the second quarter. Blair William & Co. IL now owns 2,279,647 shares of the biopharmaceutical company’s stock worth $22,614,000 after acquiring an additional 6,940 shares during the period. Marshall Wace LLP boosted its holdings in Dynavax Technologies by 12.2% in the third quarter. Marshall Wace LLP now owns 2,036,003 shares of the biopharmaceutical company’s stock worth $20,218,000 after purchasing an additional 221,069 shares during the last quarter. Bank of America Corp DE boosted its holdings in Dynavax Technologies by 25.7% in the third quarter. Bank of America Corp DE now owns 1,458,087 shares of the biopharmaceutical company’s stock worth $14,479,000 after purchasing an additional 298,106 shares during the last quarter. Glenmede Investment Management LP grew its position in Dynavax Technologies by 23.8% in the 3rd quarter. Glenmede Investment Management LP now owns 1,264,369 shares of the biopharmaceutical company’s stock worth $12,555,000 after purchasing an additional 243,240 shares during the period. Finally, Invesco Ltd. raised its stake in Dynavax Technologies by 2.7% during the 3rd quarter. Invesco Ltd. now owns 1,012,954 shares of the biopharmaceutical company’s stock valued at $10,059,000 after buying an additional 26,974 shares during the last quarter. Institutional investors own 96.96% of the company’s stock.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation is a biopharmaceutical company focused on the development and commercialization of novel vaccines and immunotherapies. Headquartered in Emeryville, California, the company specializes in leveraging its proprietary Toll-like receptor (TLR) agonist platform to enhance immune responses. Its lead product, HEPLISAV-B, is a two-dose hepatitis B vaccine approved by the U.S. Food and Drug Administration that incorporates the CpG 1018 adjuvant to stimulate a rapid and robust antibody response in adults.

Founded in 1993, Dynavax has built a pipeline that extends beyond hepatitis B to include candidates targeting seasonal influenza, respiratory syncytial virus (RSV) and emerging infectious diseases.